AZN logo

AstraZeneca

AZN · What the business does, what can go wrong, and how options sellers approach it

What it does

AstraZeneca is a global biopharmaceutical company formed by the merger of Sweden's Astra and the UK's Zeneca. It researches, develops, manufactures and sells prescription medicines.

Its main therapeutic areas include oncology, cardiovascular, renal and metabolic conditions, rare disease, and respiratory and immunology. It sells in markets around the world, and much of its revenue comes from outside the United States.

How it makes money

The company earns revenue by selling patent-protected branded medicines to hospitals, pharmacies, health systems and governments. Prices and reimbursement are shaped by regulators and insurers in each country.

A large share of income is reinvested in research. New drugs must pass clinical trials and win regulatory approval before they can be sold.

Why investors own it

  • A broad pipeline and a heavy focus on cancer treatments, a field with ongoing demand.
  • Geographic diversification across many countries.
  • Dividend income, though dividends are decided by the board and can change.
  • Exposure to long-term healthcare demand from aging populations.

What can go wrong

  • Patents expire, allowing cheaper generic or biosimilar competition.
  • Clinical trials can fail, and regulators can delay or reject approvals.
  • Drug pricing pressure from governments and insurers, especially in the US.
  • Legal claims, safety issues or manufacturing problems.
  • Currency swings, since it reports in dollars but earns and spends in many currencies.

What to watch

  • Clinical trial readouts and regulatory decisions
  • Revenue growth of its key cancer and metabolic drugs
  • Patent expiry dates for major products
  • Drug pricing and reimbursement policy changes
  • Research and development spending versus pipeline progress
  • Currency movements
  • Dividend announcements

Options income angle

Options on AZN are generally available and reasonably liquid for US-listed shares, though trading is usually thinner than for the largest US mega-cap stocks. Bid-ask spreads can be wider on far-dated or far-from-the-money strikes.

Implied volatility tends to rise ahead of earnings, major trial results and regulatory decisions, then often drops afterward. Policy news on drug pricing can also move it.

One caution for premium sellers: a single trial failure or approval setback can cause a sharp price gap down, which can leave a short put deep in the money, while a positive surprise can gap the stock above a covered call's strike and cap the gain. Check the calendar for known catalysts before choosing an expiration.

Follow AZN in Kortex

The Kortex app shows AZN's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.